Jiangsu Hengrui Medicine
600276.SS
$6.29
Share price
2.96%
Change (1 day)
-9.63%
Change (1 year)
Categories
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics
Revenue for Jiangsu Hengrui Medicine (600276.SS)
Revenue in 2023 (TTM): $3.17 B
According to Jiangsu Hengrui Medicine 's latest financial reports the company's current revenue (TTM) is $3.17 B. In 2022 the company made a revenue of $3.14 B a decrease over the years 2021 revenue that were of $4.00 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Jiangsu Hengrui Medicine from 2002 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $3.17 B | 0.74% |
| 2022 | $3.14 B | -21.35% |
| 2021 | $4.00 B | -1.43% |
| 2020 | $4.06 B | 20.96% |
| 2019 | $3.35 B | 28.68% |
| 2018 | $2.60 B | 26.23% |
| 2017 | $2.06 B | 24.3% |
| 2016 | $1.66 B | 12.63% |
| 2015 | $1.47 B | 22.49% |
| 2014 | $1.20 B | 18.95% |
| 2013 | $1.01 B | 17.25% |
| 2012 | $0.86 B | 21.81% |
| 2011 | $0.70 B | 27.29% |
| 2010 | $0.55 B | 25.54% |
| 2009 | $0.44 B | 27.52% |
| 2008 | $0.34 B | 33.31% |
| 2007 | $0.26 B | 44.72% |
| 2006 | $0.18 B | 24.95% |
| 2005 | $0.14 B | 8.62% |
| 2004 | $0.13 B | 4.67% |
| 2003 | $0.12 B | 39.02% |
| 2002 | $91.36 M |